Zealand Pharma A/S (ZEAL): Price and Financial Metrics


Zealand Pharma A/S (ZEAL): $17.59

0.21 (+1.21%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ZEAL Stock Price Chart Interactive Chart >

Price chart for ZEAL

ZEAL Price/Volume Stats

Current price $17.59 52-week high $32.94
Prev. close $17.38 52-week low $9.93
Day low $17.47 Volume 2,100
Day high $18.07 Avg. volume 4,965
50-day MA $17.62 Dividend yield N/A
200-day MA $17.38 Market Cap 818.60M

Zealand Pharma A/S (ZEAL) Company Bio


Zealand Pharma A/S, a biotech company, engages in the discovery, design, and development of novel peptide-based medicines in Denmark. The company was founded in 1997 and is based in Copenhagen, Denmark.


ZEAL Latest News Stream


Event/Time News Detail
Loading, please wait...

ZEAL Latest Social Stream


Loading social stream, please wait...

View Full ZEAL Social Stream

Latest ZEAL News From Around the Web

Below are the latest news stories about ZEALAND PHARMA A that investors may wish to consider to help them evaluate ZEAL as an investment opportunity.

Needham Sticks to Their Buy Rating for Zealand Pharma (ZEAL)

E ratio of -4.51.

Carrie Williams on TipRanks | September 30, 2022

Zealand Pharma’s (NASDAQ:ZEAL) Phase 3 SBS Trial Sees Positive Results

Biotechnology company Zealand Pharma (NASDAQ:ZEAL) has delivered positive topline results from the Phase 3 trial of glepaglutide for the treatment of short bowel syndrome (SBS). The trial met its primary endpoint and the twice-weekly dosing regimen showed a statistically significant decrease in weekly parental support at 24 weeks. The treatment was deemed safe and was well tolerated.

Kailas Salunkhe on TipRanks | September 30, 2022

Total number of shares and voting rights in Zealand Pharma at September 30, 2022

Company announcement – No. 42 / 2022 Total number of shares and voting rights in Zealand Pharma at September 30, 2022 Copenhagen, DK and Boston, MA, September 30, 2022 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with section 32 of the Danish Capital Markets Act, announces the total number of shares and voting rights in the Company at th

Yahoo | September 30, 2022

Zealand Pharma Announces Positive Results from Phase 3 Trial of Glepaglutide in Patients with Short Bowel Syndrome (EASE 1)

Company announcement – No. 41 / 2022 Zealand Pharma Announces Positive Results from Phase 3 Trial of Glepaglutide in Patients with Short Bowel Syndrome (EASE 1) Glepaglutide treatment met the primary endpoint with twice weekly dosing achieving a statistically significant reduction in weekly parenteral support volume by 5.13 Liters/week from baseline at 24 weeks66% of patients in the twice weekly group had a clinically meaningful response (>20% reduction in parenteral support volume)In total 9 pa

Yahoo | September 30, 2022

Zealand Pharma Announces Oral Presentation of Phase 2 Data for BI 456906 at the 58th Annual Meeting of the European Association for the Study of Diabetes (EASD)

Press release – No. 6 / 2022 Zealand Pharma Announces Oral Presentation of Phase 2 Data for BI 456906 at the 58th Annual Meeting of the European Association for the Study of Diabetes (EASD) BI 456906 effectively lowered HbA1c up to -1.88% at week 16 in patients with type 2 diabetes in the Phase 2 clinical trialPreclinical pharmacology of BI 456906 supports ongoing Phase 2 studies in obesity or non-alcoholic steatohepatitis Copenhagen, Denmark and Boston MA, U.S. September 21, 2022 – Zealand Phar

Yahoo | September 21, 2022

Read More 'ZEAL' Stories Here

ZEAL Price Returns

1-mo N/A
3-mo N/A
6-mo 27.19%
1-year -15.43%
3-year -46.49%
5-year 32.65%
YTD -17.57%
2021 -40.62%
2020 8.25%
2019 185.96%
2018 -14.63%
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6599 seconds.